Purpose
Our goal is to demonstrate the main findings in Computed Tomography scans of COVID-19 patients who underwent evolutionary control, considering early and late pulmonary alterations.
Methods and materials
In general, CT lesions in patients with COVID-19 progress after hospital admission, and it is reported that pulmonary changes may persist later. The resolution of the findings is usually considered to be complete by the 26th day. However, there are cases with persistent alterations even after this period and that need to be better evaluated. Patients with few lesions may not show progression, progressing directly to radiological resolution.
With the progression of the disease, between 9 and 13 days, there is the appearance of lesions...
Results
We found 137 positive COVID patients who underwent chest CT for evolutionary control during the analyzed period. Of those, 117 patients (85.4%) underwent 2 chest CT exams. 16 patients (11.7%) underwent 3 chest CT exams. 3 patients (2.9%) underwent 4 CT scans.
We had 27 patients who underwent chest CT with an interval greater than or equal to 60 days between the first and the last exam.
We observed two patients who had progressed to control chest CT with cavity lesions, which should occur due...
Conclusion
In general, lesions on chest CT show progression in the first days after the onset of symptoms, showing improvement a few weeks after the start of treatment, depending on each case. Patients with few lesions may not progress, progressing directly to radiological resolution. Some patients, may progress with fibrosis and remain with CT changes for the long term.
Some patients, especially the elderly and those who had multiple lesions and extensive involvement of the parenchyma, may progress with fibrosis and remain with CT changes for...
Personal information and conflict of interest
A. S. Santos:
Nothing to disclose
A. R. S. SANTOS:
Nothing to disclose
A. Bartholazzi:
Nothing to disclose
F. Oliveira:
Nothing to disclose
M. Bellas:
Nothing to disclose
S. Vinhas:
Nothing to disclose
R. Pereira:
Nothing to disclose
M. Damasceno:
Nothing to disclose
W. Martins:
Nothing to disclose
References
MEIRELLES, G. COVID-19: a brief update for radiologists.Radiol Bras. 2020 Set/Out;53(5):320–328.http://dx.doi.org/10.1590/0100-3984.2020.0074
Carfi A., Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA.2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.
Tale S., Ghosh S., Meitei S.P., Kolli M., Garbhapu A.K., Pudi S. Post-COVID-19 pneumonia pulmonary fibrosis. QJM.2020 Nov 1;113(11):837-838. doi: 10.1093/qjmed/hcaa255.
George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020 Aug;8(8):807-815. doi: 10.1016/S2213-2600(20)30225-3. Epub 2020 May 15.
Spagnolo P., Balestro E., Aliberti S., Cocconcelli E.,...